Objectives: Electronic health records are becoming increasingly common tools for storing and sharing patient health information. Many vendors offer patient "portals" as a way for patients and/or proxies to view test results and communicate with their health care teams. Few researchers have looked at patient portals in the inpatient pediatric population. Our objectives were to describe portal activation and use and factors associated with these end points for hospitalized children.
Methods: Retrospective, single-center study of pediatric patients birth through 17 years old who had at least one hospital admission and one or more inpatient diagnostic test performed between January 1, 2018, to December 31, 2018. Portal use was defined as viewing one or more test result. Multivariate logistic regression analyzed the association between patient characteristics and portal account activation and use.
Results: A total of 5862 patients with 170 685 diagnostic test results were included. A total of 40.9% of patients had an activated account, and 20.3% viewed one or more test result. Factors associated with an increased odds of portal activation and/or use included English as preferred language, white race, commercial insurance, multiple admissions, previous outpatient testing, and having both laboratory and imaging inpatient studies performed.
Conclusions: In this study, we highlight the underuse of the patient portal in the inpatient pediatric population, especially for patients whose preferred language is not English, self-identify as multiracial and are publicly insured or uninsured. Concerted efforts to eliminate health care disparities in relation to portal activation are needed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1542/hpeds.2020-003707 | DOI Listing |
JHEP Rep
February 2025
Department of Gastroenterology and Hepatology, Hospital Universitario Ramón y Cajal, Instituto Ramon y Cajal de Investigación Sanitaria (IRYCIS), Universidad de Alcalá, Madrid, Spain.
Background & Aims: Systemic inflammation is a driver of decompensation in cirrhosis with unclear relevance in the compensated stage. We evaluated inflammation and bacterial translocation markers in compensated cirrhosis and their dynamics in relation to the first decompensation.
Methods: This study is nested within the PREDESCI trial, which investigated non-selective beta-blockers for preventing decompensation in compensated cirrhosis and clinically significant portal hypertension (CSPH: hepatic venous pressure gradient ≥10 mmHg).
J Cutan Med Surg
January 2025
Division of Surgical Research, Head Surgical Epidemiology, McGill University, Montreal, QC, Canada.
Background: A review of Health Canada's post-market surveillance database has revealed that the reporting of adverse events (AEs) following aesthetic injectable treatments is significantly underreported. To increase reporting, investigators have recently developed a novel Electronic Data Capture system: The Global Registry of Adverse Clinical Events (GRACE).
Objective: To identify the incidence of AEs associated with aesthetic injectable treatments.
Trends Cardiovasc Med
January 2025
Department of Cardiology, Euroclinic Hospital, Athens, Greece; First Department of Cardiology, Athens University School of Medicine, Athens, Greece. Electronic address:
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty-liver disease, is an important and rising health issue with a link with atherosclerotic cardiovascular (CV) disease (CVD), affecting ∼25-30% of the adults in the general population; in patients with diabetes, its prevalence culminates to ∼70%; its evolutive form, nonalcoholic steatohepatitis, is estimated to be the main cause of liver transplantation in the future. MASLD is a multisystem disease that affects, besides the liver, extra-hepatic organs and regulatory pathways; it raises the risk of type 2 diabetes mellitus (T2D), CVD, and chronic kidney disease; the disease may also progress to hepatocellular carcinoma. Its diagnosis requires hepatic steatosis and at least one cardiometabolic risk factor and the exclusion of both significant alcohol consumption and other competing causes of chronic liver disease.
View Article and Find Full Text PDFJ Med Internet Res
January 2025
Institute for Better Health, Trillium Health Partners, Mississauga, ON, Canada.
Background: Patient portals, or secure websites linked to electronic medical records, have emerged as tools to provide patients with timely access to their health information. To support the potential benefits of patient portals such as improved engagement in health care, it is essential to understand how patients and caregivers experience these portals.
Objective: This study aimed to explore patient and caregiver experiences, facilitators, and barriers to accessing and using a patient portal called MyChart during the initial stages of its implementation.
J Med Internet Res
January 2025
Centre for Research in Media and Communication, Faculty of Social Sciences and Humanities, Universiti Kebangsaan Malaysia, Selangor, Malaysia.
Background: Cardiovascular disease (CVD) is a major global health issue, with approximately 70% of cases linked to modifiable risk factors. Digital health solutions offer potential for CVD prevention; yet, their effectiveness in covering the full range of prevention strategies is uncertain.
Objective: This study aimed to synthesize current literature on digital solutions for CVD prevention, identify the key components of effective digital interventions, and highlight critical research gaps to inform the development of sustainable strategies for CVD prevention.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!